Core Viewpoint - The article provides a detailed disassembly and analysis of the MR750-20V charging module from Magmeter, highlighting its specifications, design features, and internal components. Group 1: Product Overview - The MR750-20V charging module is designed for electric vehicles, featuring a power output of 15kW, with an input voltage of 380V three-phase AC and an output voltage range of 250-750V at a current of 20A [3][4][9]. - The module is constructed with a metal shell and includes features such as a hot-swappable design, cooling fans, and indicator lights for operational status [4][19][21]. Group 2: Internal Design and Components - The internal structure includes a single-layer PCB design with insulation materials, and the module is equipped with various electronic components such as capacitors, resistors, and integrated circuits [50][80][84]. - Key components include a PFC controller, LLC controller, and various power management ICs, which are essential for the module's functionality and efficiency [197][255][289]. Group 3: Electrical Specifications - The charging module incorporates multiple capacitors for filtering, including high-voltage electrolytic capacitors rated at 450V and 820μF, and additional film capacitors for voltage stabilization [181][227][235]. - The module features a range of protective components, including fuses rated at 30A and varistors for surge protection, ensuring safe operation under various conditions [94][100][188]. Group 4: Communication and Control - The MR750-20V includes communication interfaces for integration with vehicle systems, utilizing CAN bus technology for data transmission [267][301]. - The main control MCU is designed to operate within a wide temperature range and supports various communication protocols, enhancing the module's versatility in different applications [255][259].

智通财经APP获悉，据港交所6月27日披露，豪威集成电路(集团)股份有限公司(简称：豪威集团(603501.SH))向港交所主板递交上市申请，瑞银集团、中金公 司、PASCHK、GFSHK为联席保荐人。 此外，豪威集团于2024年新成立了的机器视觉部门。公司于2024年4月发布了OG09A10，这是我们适用于工厂自动化和ITS的大呎寸全局快门解决方案，基 于公司的专利PureCel®Plus-S晶片堆叠架构。公司还发布了由OG02B10彩色全域快门(GlobalShutter)图像传感器和OAX4000ASIC图像信号处理器(ISP)组成的 整体摄像头解决方案。除上述产品外，公司亦推出BSI像素尺寸为2.2微米的OG05B1B和OG01H1B传感器，以及BSI像素尺寸为3.45微米的OG02C10/1B、 OG03A10/1B和OG05C10/1B传感器。 业绩方面，于2022年度、2023年度、2024年度，豪威集团实现收入分别约为200.40亿元、209.84亿元、257.07亿元人民币；同期，毛利分别约为47.41亿元、 41.84亿元、72.39亿元人民币。 | 纂]項下的[编纂]數目 .. | | ...

" 野心再现，京东加速重构线下零售业态。 " 作者丨王薇 编辑丨梁辰 京东零售线下布局提速。5月22日，雷峰网查询国家企业信用信息公示系统发现，京东于15日在上海静安 区登记注册成立了一家新公司，名为"上海京东壹零壹家居购物有限公司（以下简称'上海壹零壹家 居'）"，注册资本5000万元人民币。 系统显示，该公司经营范围包括家具销售、家具零配件销售、工艺美术品及礼仪用品销售、票务代理服 务、市场营销策划等。该公司由京东五星电器集团有限公司（以下简称"京东五星"）全资持股，法定代表 人是石永刚。 | 上海京东壹零壹家居购物有限公司 + 存续 (在黄、开业、在册) | | | | 发送报告 | | --- | --- | --- | --- | --- | | 统一社会信用代码: 91310106MAEKCU6810 | | | | | | 注册号: | | | | 信息分享 | | 法定代表人: 石永刚 | | | | | | 静安区市场监督管理局 | 登记机关: | | | 信息打印 | | 成立日期： 2025年05月15日 | | | | | | 其础信息 | | 行政许可信息 行政处罚信息 列入经营异常 ...

一项由中国研究人员近日发布的最新原创性研究，有望将全球结核病预防性治疗周期由三个月缩短至 一个月。相较于WHO推荐的现行短疗程预防性治疗方案，该"中国版"超短疗程方案还有望进一步降 低治疗的药物副作用。 这项研究由国家传染病医学中心主任、广州国家实验室上海基地（上海感染与免疫科技创新中心）主 任张文宏教授团队发起。在近日刊发于Emerging Microbes & infections杂志（《新兴微生物和感 染》）、题为 "Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)"（《新型短程利福喷丁和异烟肼方案预防性治疗中国矽肺病患者结核病 的疗效和安全性：一项试点研究》，以下简称"研究"）的文章中，该研究团队首次公布这项全新超 短程结核预防治疗方案（1H3P3方案）的有效性及安全性数据。 2025.05. 2 ...

Core Viewpoint - A new short-course preventive treatment for tuberculosis (TB) in China, known as the 1H3P3 regimen, shows promise in reducing treatment duration and side effects compared to the WHO-recommended 3HP regimen, potentially improving patient adherence and outcomes [1][4][5]. Group 1: Research Background - The study was initiated by Professor Zhang Wenhong's team and published in the journal Emerging Microbes & Infections, focusing on the efficacy and safety of the 1H3P3 regimen for TB prevention in silicosis patients [2]. - Traditional TB preventive treatments have long durations and significant side effects, leading to poor patient compliance, which affects their effectiveness and coverage [1][3]. Group 2: Treatment Comparison - The WHO recommends several treatment regimens, including a 6-9 month isoniazid monotherapy and a 3-month isoniazid plus rifapentine (3HP) regimen, but the latter has shown higher adverse reaction rates in Chinese populations [3][4]. - The 1H3P3 regimen consists of rifapentine (450mg) and isoniazid (400mg) administered three times a week for four weeks, aiming to reduce single-dose side effects and improve adherence [4][5]. Group 3: Study Results - The study included 238 participants, with only 2.5% diagnosed with active TB after three years, indicating a significant reduction in TB incidence compared to the 3HP regimen [5][6]. - The 1H3P3 regimen demonstrated a 74% reduction in the risk of developing active TB, with a treatment completion rate of 92%, significantly higher than the 54.7% completion rate for the 3HP regimen [6][7]. Group 4: Future Directions - The research team plans to conduct further studies on the 1H3P3 regimen in broader high-risk populations, including close contacts of TB patients, and aims to develop a combination formulation to simplify treatment [7][8]. - There is a need for increased government investment and collaboration across sectors to enhance public awareness and acceptance of TB preventive treatments [8].

·2025年一季度中国家具行业进出口报告出炉 ·中国进口消费品价格指数首次发布 家居类环比下跌13.1% 来源：环球网 ·4月全国林业采购经理指数发布 木质家具行业全线下滑 ·一季度家具类商品投诉增长41.55% ·4月全国建材家居卖场销售额环比下跌15.14% 同比下跌2.52% ·第三届中国·兰考定制家居博览会开幕 ·悍高集团IPO注册申请获批 ·好博窗控深交所IPO终止 ·皮阿诺旗下电竞房品牌"燃刻"首店启幕 ·顾家家居副总裁姚斌辞职 ·红星美凯龙创始人车建兴被立案留置 ·博洛尼海外三店齐开 加速东南亚布局 ·京东全球家居好物旗舰店上线 年底开首家实体店 ·贝壳一季度家装家居净收入增22%至29亿 贡献利润率创新高 ·国誉家具C³office中国首店在沪启幕 5月10日，中国进口消费品价格指数发布，这是国内首个反映进口消费品价格波动的综合指数，填补了 我国进口消费市场价格监测的空白。首期发布数据显示，3月中国进口消费品价格环比增长7.2%，同比 增长5.2%，呈现环比、同比双增长态势。与此同时，结构性分化特征较为显著，个护文体类受益于节 庆效应拉动，环比增长29.5%；电子文娱类在智能设备迭代驱动下环比 ...

在业绩向好的同时，寒武纪的存货和预付款激增。到2025年 一季度，寒武纪的存货已经升至27.55亿元，这是寒武纪历年 最高的存货水平。 作者： 冯雨晨 封图：图虫创意 "AI芯片第一股"寒武纪（688256.SH）连续两个季度交出盈利成绩单，5月12日，寒武纪召开2024 年暨2025年一季度业绩说明会。 在互动提问环节，投资者对寒武纪的存货与预付款激增、研发投入计划、一季度业绩增长动因等问 题关注度较高。 寒武纪正处于转盈的关键时刻。2020年至2024年，寒武纪5年累计收入为26.18亿元，累计亏损达 到38.16亿元。在2024年第四季度，寒武纪以2.72亿元的净利润首次实现单季度盈利转正，2025年 一季度，寒武纪继续盈利3.55亿元。 在业绩向好的同时，寒武纪的存货和预付款激增。2024年半年报中，寒武纪存货为2.35亿元，至 2024年三季度末，寒武纪存货跃至10.15亿元，到2025年一季度，寒武纪的存货已经升至27.55亿 元，这是寒武纪历年最高的存货水平。 一同处于历史最高水平的，还有寒武纪的预付账款，2025年一季度末，这一数字达到了9.73亿 元。 面对投资者的疑问，寒武纪称2024年存 ...

4月30日晚，寒武纪发布定增预案称，为进一步增强公司综合竞争力，公司拟向特定对象发行A股股票 募资不超过49.8亿元。 根据公告，本次融资将分三部分使用：面向大模型的芯片平台项目拟投资金额为29亿元，面向大模型的 软件平台项目拟投资金额为16亿元，补充流动资金金额为4.8亿元。 值得注意的是，由于芯片行业具有高投入、长周期特征，寒武纪的研发投入一直处于高位。近五年，寒 武纪投入的研发费用累计已超57亿元。2020年至2024年，寒武纪的研发费用分别为7.68亿元、11.36亿 元、15.23亿元、11.18亿元、12.16亿元，均超当年的营收。 2020年至2024年，寒武纪实现营业收入分别为4.59亿元、7.21亿元、7.29亿元、7.09亿元、11.74亿元。 高额的研发费用也导致了寒武纪长期处于亏损状态，同期，归母净亏损分别为4.35亿元、8.25亿元、 12.57亿元、8.48亿元、4.52亿元。 不过，这种局面已在2024年第四季度迎来了转机。该季度中，寒武纪实现营收为9.89亿元，同比增长 75.51%；净利润为2.72亿元，同比增长768.58%，实现扭亏为盈。进入2025年一季度，受国产大模型 ...

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and pr ...

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [2] - The company is participating in two upcoming investor conferences, indicating active engagement with the investment community [1][3] Company Overview - Revolution Medicines specializes in RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [2] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), all of which are in clinical development [2] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [2] - Additional pipeline opportunities include RMC-0708 (Q61H) and RMC-8839 (G13C), focusing on RAS(ON) mutant-selective inhibitors [2] Upcoming Events - The company will participate in the Needham 24 Annual Virtual Healthcare Conference on April 7 at 2:15 p.m. ET [3] - Additionally, Revolution Medicines will be part of the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 1:00 p.m. ET [3]